|
Kelly
i just went over the original article--yes her2+ breast cancer patients have a proclivity to metastasize to the brain
Only 30 of the her2+ early breast cancer patients in this study got herceptin as part of a clinical trial, so it was not herceptin which was affecting where the mets presented or didn't present in the majority of cases (some say herceptin is changing the natural history of the disease by preventing most of the liver, bone and lung mets but being unable to prevent the brain mets due to its inability to cross the blood-brain barrier)
Of the her2+ patients who developed brain mets, it seems more were ER- than ER+
Hope this helps!
|